House Oversight Subcmte. reviewing FDA ad division notice of violation letters.

HOUSE OVERSIGHT SUBCMTE. REVIEWING FDA AD DIVISION VIOLATION LETTERS and may release them this autumn once the subcommittee's ongoing investigation of 163 notice-of-violation letters written by FDA's Division of Drug Marketing, Advertising & Communications in 1995 is complete. DDMAC issued no warning letters during 1995.